Precigen: Has To Grow Into Its Valuation
Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $18
Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript
HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $14 Price Target
Precigen Inc (NASDAQ:PGEN) Flashes Perfect Technical Rating and Explosive Sales Growth in Minervini Screen
Precigen: Entering The Oncology 'Sweet Spot'
Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $14
Precigen Says FDA Grants Orphan Drug Exclusivity For PAPZIMEOS For Treatment Of Adults With Recurrent Respiratory Papillomatosis
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
Precigen (PGEN): The Best Penny Stock to Buy for Long Term
Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)
Earnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Precigen, Inc. Q1 2026 Earnings Call Summary
Citizens Maintains Market Outperform on Precigen, Raises Price Target to $11
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $11
Precigen Inc (PGEN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.